Woodford Woes Drag On For Immunocore
Unrealistic Valuations Holding Private Firms Back
Executive Summary
Once seen as the champion of biotech start-ups, Woodford’s blind faith has shackled firms to unrealistic valuations.
You may also be interested in...
Troubled Immunocore Reawakens With New $130m Funding
After a record breaking Series A fundraising, the UK biotech hit a series of problems. Can a new CEO and new funding help it fulfil its promise?
Autolus Faces Life After Woodford With New Czech Backer
PPF has bought a big stake in the UK-based T-cell specialist, one of many firms backed by investor Neil Woodford which have suffered stock slides in the past few months.
Investor Faith In David Hung’s Nuvation Renewed By Anheart Buyout
The acquisition brings two potential best-in-class cancer therapies, which could make Nuvation a commercial company as soon as 2025.